Patents Assigned to InNexus Biotechnology International Limited
-
Publication number: 20120052068Abstract: Antibodies having noncovalent, autophilic properties are disclosed. The autophilic antibodies are derived from antibodies conjugated with an autophilic peptide. Such autophilic antibodies can promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Compositions containing the antibodies, and methods of making and using the antibodies are also disclosed.Type: ApplicationFiled: August 23, 2011Publication date: March 1, 2012Applicant: InNexus Biotechnology International LimitedInventors: Heinz Kohler, Sybille Muller, Alton C. Morgan
-
Publication number: 20090317379Abstract: Antibodies having noncovalent, autophilic properties are disclosed. The autophilic antibodies are derived from antibodies conjugated with an autophilic peptide. Such autophilic antibodies can promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Compositions containing the antibodies, and methods of making and using the antibodies are also disclosed.Type: ApplicationFiled: June 9, 2009Publication date: December 24, 2009Applicant: InNexus Biotechnology International LimitedInventors: Heinz Kohler, Sybille Muller, Alton Charles Morgan, JR.
-
Publication number: 20090274710Abstract: Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases.Type: ApplicationFiled: April 9, 2009Publication date: November 5, 2009Applicant: InNexus Biotechnology International LimitedInventors: Heinz Kohler, Sybille Muller, Thomas L. Brown, Yunfeng Zhao, A. Charles Morgan, JR.
-
Patent number: 7569674Abstract: Antibodies having noncovalent, autophilic properties are disclosed. The autophilic antibodies are derived from antibodies conjugated with an autophilic peptide. Such autophilic antibodies can promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Compositions containing the antibodies, and methods of making and using the antibodies are also disclosed.Type: GrantFiled: April 29, 2005Date of Patent: August 4, 2009Assignee: InNexus Biotechnology International LimitedInventors: Heinz Kohler, Sybille Muller
-
Publication number: 20090075339Abstract: Autophilic antibodies including an immunoglobulin component and an autophilic peptide fused thereto are provided according to embodiments of the present invention. Particular autophilic antibodies described herein include a chimeric gamma immunoglobulin heavy chain and autophilic peptide expressed as a fusion protein. Preferably the autophilic peptide is expressed at the C-terminus of the immunoglobulin component. Expression vectors according to embodiments of the present invention for use in generating autophilic antibodies are provided which include a first nucleic acid sequence encoding an autophilic peptide, operably linked to a transcription promoter. In particular embodiments, a second nucleic acid sequence encoding a chimeric heavy chain of an immunoglobulin operably linked to the transcription promoter and connected to the first nucleic acid sequence such that expression of the first and second nucleic acid sequences produces a fusion protein of the chimeric heavy chain and the autophilic peptide.Type: ApplicationFiled: June 23, 2008Publication date: March 19, 2009Applicant: InNexus Biotechnology International LimitedInventors: Heinz Kohler, Jean Davin Amick, Michael A. Russ